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Abstract
Background: Detection of genital HPV DNA is recommended as an important strategy for modern cervical cancer
screening. Challenges include access to services, the reliance on cervical samples taken by clinicians, and patient’s
preference regarding provider gender. The objective of this research was to determine the acceptability, feasibility
and performance of alternative self-collected vaginal samples for HPV detection among Ghanaian women.
Methods: A comparative frequency-matched study was conducted in a systematic (1:5) sample of women attending
HIV and outpatient clinics in the Cape Coast Teaching Hospital, Ghana. Participants were instructed on self-collection
(SC) of vaginal samples using the careHPV brush and a clinician-collected (CC) cervical sample was obtained using a
similar brush. Paired specimens were tested for HPV DNA (14 high-risk types) by careHPV assay (Qiagen) and by HPV
genotyping (Anyplex II, Seegene).
Results: Overall, 194 women of mean age 44.1 years (SD ± 11.3) were enrolled and 191 paired SC and CC results
were analysed. The overall HPV detection concordance was 94.2% (95%CI: 89.9–97.1), Kappa value of 0.88 (p < 0.
0001), showing excellent agreement. This agreement was similar between HIV positive (93.8%) and negative (94.
7%) women. Sensitivity and specificity of SC compared to CC were 92.6% (95%CI: 85.3–97.0) and 95.9% (95%CI:
89.8–98.8) respectively. The highest sensitivity was among HIV positive women (95.7%, 95%CI: 88.0–99.1) and
highest specificity among HIV negative women (98.6%, 95%CI: 92.4–100). Overall, 76.3% women found SC very
easy/easy to obtain, 57.7% preferred SC to CC and 61.9% felt SC would increase their likelihood to access cervical
cancer screening.
Conclusions: The feasibility, acceptability and performance of SC using careHPV support the use of this alternative
form of HPV screening among Ghanaian women. This could be a potential new affordable strategy to improve uptake
of the national cervical cancer screening program.
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Background
In Ghana, as in many parts of sub-Saharan Africa, cer-
vical cancer is the commonest cancer and the leading
cause of cancer-related mortality among women, with an
estimated 3052 new case and 1556 deaths in Ghana an-
nually [1]. The human papillomavirus (HPV) has been
aetiologically linked to the development of cervical can-
cer (and other genital cancers) with persistence of infec-
tion with high-risk (hr) oncogenic HPV genotypes in the
transformation zone of the cervix as the main contribut-
ing factor [2]. The prevalence of HPV is high in West
Africa with an average of 20% among women without
any abnormal cytology compared to an average 12%
worldwide [3, 4]. Information on HPV prevalence and
genotype distribution among Ghanaian women is lim-
ited, but available data suggest a significant burden and
contribution to cervical cancer [5, 6].
The diagnosis of cervical cancer relies on the detection
of precursor lesions using conventional cytology with
pap smear, visual inspection using acetic acid or Lugol’s
iodine (VIA/VILI) or colposcopy with histological con-
firmation, with varying performance characteristics for
all of these tests and several limitations for implementa-
tion in low-resource settings [7].
Detection of hrHPV types has important prognostic
value for the detection of high-grade cervical squamous
intraepithelial lesions (HSIL) or neoplasia (CIN) [8].
Diagnosing HPV infection and its associated clinical
conditions in Ghana is very challenging. The challenges
include, but are not limited to, low levels of awareness
in the general population [9] and the reliance on cervical
samples taken by clinicians for diagnosis. The problem
of clinician collection of cervical samples may limit ac-
ceptability and hence coverage of screening for various
reasons. In industrialized countries, this could include
the busy lifestyle of women who may not have the time
to go to the clinic to have the sample taken, and the re-
luctance of some women to attend health facilities.
Thus, any screening program which must be done in a
clinic setting may not be suitable. In addition, the sam-
ple collection procedure requiring the passing of a vagi-
nal speculum is uncomfortable and hence may act as a
deterrent. The issue gets more complex in the diverse
socio-cultural settings in Africa. Cultural beliefs frown
upon another person aside the husband having access to
the genital area of a female. A recent study in Ghana
using a mixed methods approach confirmed that one
barrier to cervical cancer screening mentioned by
women was the cultural belief that it is inappropriate for
another person to see a woman’s genital area [10].
Since highly sensitive molecular testing for HPV does
not necessarily require exact cervical location of HPV
replication (i.e. the squamo-columnar junction or trans-
formation zone) to be collected, contrary to what
cervical cytology requires, an additional potential benefit
of HPV testing is the possible use of self-collected
cervico-vaginal samples. It has been shown that self-
collection might be preferred by women as it addresses
issues affecting clinician sample collection [11–13]. Tay-
lor et al. in their recent systematic review of self-
sampling for sexually transmitted infections including
HPV screening concluded that in addition to being ac-
ceptable to patients, this might also be a cost effective
method [14]. Despite evidence of higher acceptability of
self-collection, there is the need to evaluate the perform-
ance of such samples for HPV detection and to deter-
mine the views of women in a range of settings and
backgrounds. This study sought to determine the per-
formance of self-collected (SC) cervico-vaginal samples
for HPV detection compared to clinician collection (CC)
and to assess the preferred sampling method for women
in the specific socio-cultural setting of Ghana.
Methods
Study subjects
Participants were recruited as part of a larger HPV and
cervical cancer study conducted in the Cape Coast
Teaching Hospital (CCTH), aiming at studying the epi-
demiology of, and diagnostic options for hrHPV and cer-
vical lesions among HIV-1 seropositive compared with
HIV-seronegative women. In the parent study, women
attending the general medical outpatient and HIV clinics
of CCTH were recruited. Every fifth woman aged
≥18 years was systematically selected from the list of
daily attendants, starting with a randomly picked attend-
ance number for the first woman. If a woman was
deemed not eligible based on criteria for this study (cur-
rently menstruating, previous treatment of cervical can-
cer etc.), or she did not accept to be part of the study,
the next available patient was offered her place, and
every fifth woman whence, to a maximum of 10 women
per clinic day was recruited. For the current evaluation
of self-sampling, we aimed to have about half the sample
size and participants were recruited on alternate days.
Sample collection
To simulate home-based sampling, recruited participants
at the clinic were instructed on how to obtain SC vaginal
samples using the careHPV brush and to place it in the
careHPV collection medium (Qiagen, Gaithersburg, MD).
Participants then underwent a speculum exam during
which clinicians collected a cervical sample using the car-
eHPV brush and transport medium. After sample collec-
tion, participants filled a short questionnaire to assess
their experience and views of SC compared with CC. The
questionnaire was administered by the clinician who col-
lected the sample. Four questions were asked, with two
using a Lichter’s scale of possible responses (Table 2).
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HPV DNA detection
Paired SC and CC samples were tested using the car-
eHPV assay (Qiagen, Gaithersburg, MD) following the
manufacturer’s instructions. careHPV is a semi-rapid
qualitative assay designed as a simplification of the
Digene Hybrid Capture-II (HC2) test technology to de-
tect the DNA of any of 14 hrHPV types (HPV16, 18, 31,
33, 35, 39, 45, 52, 56, 58, 59, 68, with HPV66 being an
addition to the 13 hrHPV detected by HC2) [15–17].
The assay has been designed for use in resource-
constrained settings with little need for refrigeration of
samples prior to testing and using portable battery-
operated reading machine. careHPV has been favourably
evaluated in comparison to HC2 and other HPV detec-
tion assays for the detection of high-grade cervical le-
sions [18, 19].
In addition, HPV genotyping was done to verify type-
specific concordance. An aliquot from each of the cer-
vical and vaginal samples were tested using the Anyplex™
II HPV HR Detection assay (Seegene, South Korea)
which detects 28 HPV types, including the same 14
hrHPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
68) detected by careHPV. This assay has been validated
against an international reference method [20].
Sample size and statistical analysis
A Kappa calculation was performed to determine the
sample size needed for this sub-study. A Kappa value of
0.75 or higher was taken to indicate excellent agreement.
Assuming a ≤ 10% difference in levels of detection be-
tween SC vaginal samples versus comparator standard
CC cervical sampling, it was estimated that a total of
150 paired SC and CC samples were needed.
The proportion of overall careHPV results agreement
between paired SC and CC samples was calculated using
the Kappa statistic. Sensitivity and specificity of SC com-
pared to CC as the gold standard were also calculated
with their 95% confidence intervals (CI). A genotype
level analysis of concordance was also conducted. To de-
termine the acceptability of SC and CC, the proportions
of responses to questions asked concerning the experi-
ence of participants was calculated.
Ethics
Ethical approval for the parent and this sub-study was
obtained from the Committee on Human Research Pub-
lications and Ethics of the School of Medical Sciences,
Kwame Nkrumah University of Science and Technology
(KNUST). Study participants were recruited to this sub-
study after obtaining additional signed written informed
consent.
Results
Between July 2014 and August 2015, a total of 333 women
were recruited to the parent study (mean age 44.1 years,
standard deviation [SD] ±11.2 years, 48.9% HIV-positive),
of whom 195 eligible women were invited to be part of
this sub-study. In all, 194 consenting women (mean age
44.1 years, SD ±11.3 years, 50% HIV-positive) provided
paired SC and CC samples. careHPV invalid results rate
after retesting was 1.5% (n = 3) and results from these
women were excluded from the analysis.
Concordance between SC and CC: careHPV results and
genotypes
The overall careHPV concordance between the remaining
191 paired samples was 94.2% (Kappa = 0.88, p ≤ 0.0001)
showing excellent agreement with similar high agreement
among HIV seropositive (Kappa = 0.84, p < 0.0001) and
seronegative (Kappa = 0.86, p < 0.0001) women (Table 1).
The sensitivity of SC compared to CC was 92.6% (95%CI:
85.3–97.0%) and specificity was 95.9% (95%CI: 89.8–
98.9%). The sensitivity was higher among HIV-
seropositive women (95.7%, 95%CI: 88.0–99.1) and speci-
ficity was higher among HIV-seronegative women (98.6%,
95%CI: 92.4–100) (Table 1). The ability to take a good SC
sample, defined as providing SC sample which produced
the same result as the CC sample, was not affected by age
(p = 0.570), educational level (p = 0.482), or HIV status
(p = 1.000).
Among HIV positive women, for twelve (12) of the
hrHPV types detected by careHPV, the positive agree-
ment between SC and CC samples was 100%. For HIV
negative women, the positive agreement between SC and
CC samples was 100% for ten (10) hrHPV genotypes.
Table 1 Performance characteristics of SC samples compared with CC for 191 women and then by HIV status
Parameter Overall (N = 191),
% (95%CI)
HIV positives (N = 96),
% (95%CI)
HIV negatives (N = 95), % (95%CI)
Concordance 94.2 (89.9–97.1) 93.8 (81.7–94.9) 94.7 (82.8–95.6)
Kappa value 0.88 (0.82–0.95) 0.84 (0.72–0.96) 0.88 (0.73–0.98)
Kappa p value <0.0001 <0.0001 <0.0001
Sensitivity 92.6 (85.3–97.0) 95.7 (88.0–99.1) 83.3 (62.6–95.3)
Specificity 95.9 (89.8–98.9) 88.5 (69.8–97.6) 98.6 (92.4–100)
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The lowest positive agreement rates (50%) was among
HIV negative women for HPV39 (Table 2).
The performance of careHPV compared with genotyp-
ing for women with cytological endpoint is presented else-
where [21]. All women were followed up with cytology
tests and management by a gynecologist, as appropriate.
Acceptability of self-collection
Responses showed that over three quarters (76.3%) of
women felt it was easy or very easy to self-collect vaginal
samples and 77.9% felt SC was very comfortable or
somehow comfortable compared with CC. Given the op-
tion, the majority of women (57.7%) would prefer SC
over CC and nearly two-thirds (61.9%) felt SC would in-
crease their likelihood to access cervical cancer screen-
ing (Table 3).
Discussion
The study found that nearly all women could obtain a
self-collected vaginal sample giving valid HPV results, and
that they felt the method was acceptable and easy to use.
Furthermore, the agreement between self-collected and
clinician-collected samples for careHPV was excellent.
This was equally the case for HIV sero-positive women
and sero-negative women. Not surprisingly, the sensitivity
of SC was higher among HIV sero-positive women since
they have a higher risk of HPV infection, whilst specificity
was highest among HIV sero-negative women. At the
genotype level, the lowest degree of concordance was 50%
for HPV39 among HIV negative women, but for the ma-
jority of hrHPV genotypes concordance was 90–100%
among both groups. This study supports self-collection of
vaginal sample as an excellent alternative sampling
method for hrHPV detection, as found by others [13,
22–24], which could improve uptake and coverage of
cervical cancer screening programs in low-resource
settings [12]. Self-sampling offers many advantages,
such as the ability to choose the time and place of
collection, which, coupled with the stability of car-
eHPV in the field (no need of refrigeration) and its
performance to detect hrHPV infection, makes it a
relevant approach for community level screening. In
such campaigns, women could obtain samples at their
homes, which could be brought to, or collected by,
community health workers who would forward them
to the laboratory. Results could easily and quickly be
communicated back to the women without having to
come to the health facility. With such a setup, only
women who need follow-up tests like cytology or col-
poscopy would be invited to health facilities. This
would alleviate the costs and burden on health ser-
vices. The Community-based Health Planning and
Services (CHP) concept, which already exists in
Ghana, makes this a potentially easily adoptable strat-
egy. Based on this concept, another research team is
currently working on evaluating self-collection at the
community-level in the Volta Region of Ghana.
In this study SC samples were taken with the same brush
as for CC sampling without the need to purchase additional
devices specifically marketed for SC, including the Delphi®
screener (Delphi Biosciences, The Netherlands) and the
Evalyn® brush (Rovers Medical Devices, The Netherlands).
Table 2 Positive agreement between clinician-collected (CC) and self-collected (SC) careHPV samples for the detection of 14 high-risk
HPV genotypes among 191 women in Cape Coast Teaching Hospital, Ghana
hrHPV
genotype
HIV POSITIVE (N = 96) HIV NEGATIVE (N = 95)
CC SC, n (%) aPositive Agreement, % CC SC, n (%) aPositive Agreement, %
16 12 (12.5) 12 (12.5) 100 1 (1.1) 1 (1.1) 100
18 12 (12.5) 12 (12.5) 100 2 (2.1) 2 (2.1) 100
31 12 (12.5) 12 (12.5) 100 0 (0.0) 0 (0.0) 100
33 7 (7.3) 7 (7.3) 100 5 (5.3) 5 (5.3) 100
35 13 (13.5) 13 (13.5) 100 4 (4.2) 3 (3.2) 75.0
39 6 (6.3) 6 (6.3) 100 2 (2.1) 1 (1.1) 50.0
45 7 (7.3) 7 (7.3) 100 1 (1.1) 1 (1.1) 100
51 1 (1.0) 1 (1.0) 100 0 (0.0) 0 (0.0) 100
52 14 (14.5) 14 (14.5) 100 1 (1.1) 1 (1.1) 100
56 8 (8.3) 8 (8.3) 100 3 (3.1) 2 (2.1) 66.7
58 13 (13.5) 14 (14.5) 92.9 4 (4.2) 5 (5.3) 80.0
59 5 (5.2) 5 (5.2) 100 0 (0.0) 0 (0.0) 100
66 4 (4.2) 5 (5.2) 80.0 2 (2.1) 2 (2.1) 100
68 9 (9.4) 9 (9.4) 100 1 (1.1) 1 (1.1) 100
aThe definition of “positive agreement” is proportion of individuals with concordant CC and SC samples test results
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Thus, by using careHPV SC came at no additional cost - an
important consideration in a developing country like
Ghana.
This study reported that three-quarters of women found
SC to be more acceptable than CC. Having experienced
both SC and CC, the participants could give a realistic ac-
count of their experience and determine their preference.
Researches in other settings, including rural communities,
have reported similar findings [11, 25]. Trope et al. in their
community-based screening study comparing SC and CC
using careHPV among 431 women in rural Thailand re-
corded over 90% acceptability with over 70% of respon-
dents indicating a preference for SC [26]. Even if women
came to health facilities for screening, the use of SC may
still increase acceptability of testing by solving the cultural
and other challenges associated with CC. Furthermore, SC
would help reduce the workload of health workers by
eliminating or reducing the need to take all samples for
HPV testing. However, some women may experience diffi-
culties in self-collecting swabs for physical reasons, such
as arthritis. In these cases, clinician sampling is preferable.
This study had some limitations. First, it used a quan-
titative approach to determine acceptability of self-
collection. A complementary qualitative methodology
would have enabled a better exploration of the women’s
experience and potential difficulties. Second, women
were recruited in a clinic setting, which increases the
chances of participation, compliance with methodology
and a positive outcome, as noted by others [24]. A larger
community-based study, currently ongoing in the Volta
Region, is required to determine the true acceptability
and validity of self-collection in the context of mass
screening in Ghana. Despite these limitations, this study
provides useful encouraging addition to the limited data
in Ghana on the role of self-collection of genital samples
for hrHPV detection.
Conclusion
This study therefore concludes that, the feasibility, accept-
ability and performance of vaginal self-collection using the
careHPV assay support it as a good alternative for hrHPV
testing Ghana.
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Table 3 Acceptability of self-collection compared with clinician
collection of samples for HPV screening among 194 women at
Cape Coast Hospital, Ghana
Item Parameter Options Grade Responses
n (%)
1 How easy was SC
for you?
Very easy 1 36 (18.6)
Easy 2 112 (57.7)
Difficult 3 45 (23.2)
Very Difficult 4 1 (0.5)
2 How comfortable was
the process
of SC compared
with CC?
Very comfortable 1 31 (16.0)
Somewhat
comfortable
2 120 (61.9)
Somewhat
uncomfortable
3 43 (22.2)
Very
uncomfortable
4 0 (0.0)
3 If you had the option,
will you prefer SC or CC
(having experienced both)?
SC 112 (57.7)
CC 76 (39.2)
Not sure 6 (3.1)
4 Do you think SC method
will make you more likely
to have cervical cancer
screening?
Yes 120 (61.9)
No 22 (11.3)
Not sure 52 (26.8)
SC self-collected, CC clinician-collected
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